Search companies

Live

Tuesday, 17 November 2026 · 580 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Tetratherix Reports First Product Revenue as FDA Seeks Further Tegenix Details

TTX: $5.50 +2.80% · MC: $340M

Tetratherix generated its first product revenue after shipping STEPP polymer to US partner Superpower Health, ahead of a planned launch next year. The FDA confirmed core elements of the Tegenix submission but requested further chemical characterisation and labelling details. The company ended the quarter with approximately $26 million in cash after an $8 million decrease, and said TetraDerm trial treatment was complete with results still blinded. Following Nexia’s resignation, BDO was appointed auditor, subject to shareholder approval at the upcoming AGM.

Source announcements: 2026-10-30 08:36 to 2026-10-30 14:54 Sydney time
Story updated 2026-10-30 15:24 Sydney time
SourcesQuarterly Activities/Appendix 4C Cash Flow ReportDetails of Auditor Appointment/Resignation
Comments